Inhibiting the signaling from VEGF and VEGFR interaction by monoclonal antibodies (bevacizumab or ramucirumab) or small molecules (sorafenib, lenvatinib, cabozantinib) has shown effectiveness in various types of cancer. The gene discussed is KDR; the disease is cancer.